Sanofi GCVRZ 深 沪
交易中
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 --
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
04-30 01:57
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by strong Dupixent growth.
04-23 23:02
Earnings Scheduled For April 23, 2026
Companies Reporting Before The Bell • Popular (NASDAQ:BPOP) is estimated to rep...
04-23 19:11
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
04-23 02:20
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision
Sanofi says FDA delays Sarclisa SC review to July while expanding Tzield use to younger children with type 1 diabetes.
04-22 19:35
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
04-18 02:20
Novavax Faces Shareholder Revolt As Shah Capital Criticizes Strategy
Shah Capital plans to oppose Novavax board and pay, citing weak returns, high costs, and strategic missteps despite the vaccine pipeline.
04-08 22:54
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technology, expanding its pipeline.
04-07 20:54
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.
04-07 19:02
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
